EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.

doi:10.1016/j.chembiol.2014.09.017

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.

Chemistry & biology - 20 Nov 2014

Bradley William D, Arora Shilpi, Busby Jennifer, Balasubramanian Srividya, Gehling Victor S, Nasveschuk Christopher G, Vaswani Rishi G, Yuan Chih-Chi, Hatton Charlie, Zhao Feng, Williamson Kaylyn E, Iyer Priyadarshini, Méndez Jacqui, Campbell Robert, Cantone Nico, Garapaty-Rao Shivani, Audia James E, Cook Andrew S, Dakin Les A, Albrecht Brian K, Harmange Jean-Christophe, Daniels Danette L, Cummings Richard T, Bryant Barbara M, Normant Emmanuel, Trojer Patrick

Abstract excerpt

The histone lysine methyltransferase (MT) Enhancer of Zeste Homolog 2 (EZH2) is considered an oncogenic driver in a subset of germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) and follicular lymphoma due to the presence of recurrent, monoallelic mutations in the EZH2 catalytic domain. These genomic data suggest that targeting the EZH2 MT activity is a valid therapeutic strategy for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histones

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lymphoma, Large B-Cell, Diffuse

Share to Lymphoma, Non-Hodgkin

Share to Methylation

Share to Mice, Nude

Share to Polycomb Repressive Complex 2

Share to Small Molecule Libraries

Share to Transplantation, Heterologous

Source

Open in PubMed

Identifiers

PMID: 25457180
DOI: 10.1016/j.chembiol.2014.09.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.PMID 25457180Read ↗

Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.Semantic proximity Read ↗

EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.Semantic proximity Read ↗

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.Semantic proximity Read ↗

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.Semantic proximity Read ↗

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.Semantic proximity Read ↗

Treating lymphoma is now a bit EZ-er.Semantic proximity Read ↗

A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.Semantic proximity Read ↗

EZH2: an epigenetic gatekeeper promoting lymphomagenesis.Semantic proximity Read ↗

Mechanisms of action and resistance in histone methylation-targeted therapy.Semantic proximity Read ↗

Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancersSemantic proximity Read ↗

The biology of novel dual histone methyltransferase inhibitorsSemantic proximity Read ↗

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.